
Omnicell (OMCL) Stock Forecast & Price Target
Omnicell (OMCL) Analyst Ratings
Bulls say
Omnicell Inc. is experiencing a positive trajectory in its financial performance, highlighted by the increasing contribution of Advanced Services to total revenue, which is projected to represent 52% of 2024 estimated revenue, demonstrating a focus on innovative solutions such as the compounding robot-as-a-service. The company's revised guidance for the fourth quarter implies significant growth expectations, with revenue and adjusted EBITDA anticipated to rise by 11% and 34%, respectively, underscoring an improving sales environment for healthcare technology investments. Additionally, the strategic review has positioned Omnicell to enhance synergies and recurring revenues, which now account for approximately 50% of total revenues, thereby supporting a sustainable growth outlook in the medication management sector.
Bears say
Omnicell Inc. is experiencing a challenging financial landscape, characterized by a decline in AEBITDA margin, which has decreased by 150 basis points year-over-year to 10.5%. The company's revenue growth estimate for 2025 has been moderated to 6%, down from a prior estimate of 9%, indicating a cautious outlook due to the anticipated slowing in the XT replacement cycle, despite growth in services revenue. Additionally, delays in the launch of the new IVX compounding robot due to regulatory redesign issues pose potential risks to future product sales and overall revenue performance.
This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.
Omnicell (OMCL) Analyst Forecast & Price Prediction
Start investing in Omnicell (OMCL)
Order type
Buy in
Order amount
Est. shares
0 shares